<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005110'>Atrial fibrillation</z:hpo> is the most common form of <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> and one of the most frequent causes of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Several new <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> have recently been introduced as alternatives to <z:chebi fb="6" ids="28384">vitamin-K</z:chebi> <z:chebi fb="68" ids="48706">antagonists</z:chebi> for prophylaxis of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> and tested in phase-3 studies for efficacy and safety </plain></SENT>
<SENT sid="2" pm="."><plain>Identifying patients who will profit in particular from the new <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy is crucial to the clinical application of these drugs </plain></SENT>
<SENT sid="3" pm="."><plain>Vernakalant and <z:chebi fb="0" ids="50659">dronedarone</z:chebi> are new antiarrhythmic drugs for rhythm control of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>However, therapeutic efficacy of the new agents still has to be proven </plain></SENT>
</text></document>